Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

High levels of PEA-15 shrink breast cancer tumors

21.04.2009
Mouse model findings indicate protein is new, important target for therapy

Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research.

Human breast cancer grafts in mice dropped to nearly undetectable levels after 35 days when treated with an adenoviral PEA-15 vector that overexpressed the protein in tumors.

"Treated mice had a dramatic response, while tumors continued to grow in control mice," said first author and presenter Chandra Bartholomeusz, M.D., Ph.D., a post-doctoral fellow in M. D. Anderson's Department of Breast Medical Oncology. Bartholomeusz presented the findings at a minisymposium titled "Up and Coming Targeted Biologic Strategies."

"This first animal model experiment demonstrates the therapeutic potential of PEA-15," said senior author Naoto Ueno, M.D., Ph.D., associate professor of breast medical oncology. "PEA-15 is a different way of modulating growth because it's based on location of the protein in the cell rather than, for example, protein regulation by phosphorylation."

Ueno and colleagues previously showed that PEA-15 stymied ovarian cancer in lab experiments, and that high expression of the protein in tumors is tied to improved overall survival. They had also examined PEA-15 expression in 26 breast cancer specimens and found the protein was more heavily expressed in the 13 low-grade tumors analyzed.

In the breast cancer experiments, the team first tested overexpression in three breast cancer cell line cultures. Lines treated with PEA-15 developed 30 to 60 percent fewer colonies of cancer cells than did control cultures. Further analysis of one cell line showed that adenovirally delivered PEA-15 overexpression inhibited cell growth and reduced DNA synthesis.

They also found that activated ERK - a protein active in growth, differentiation and mobility of cells that can fuel cancer growth when in the nucleus - was sequestered in the cell's cytoplasm. This is consistent with previous research by Ueno's team that showed PEA-15 works by binding and dragging ERK and phosphorylated ERK from the nucleus, inducing cell death.

Cell cycle analysis indicated the onset of apoptosis - programmed cell death - in breast cancer cells treated with PEA-15. In the case of ovarian cancer, the team found evidence of death by autophagy - cellular self-consumption - rather than apoptosis. The varied forms of cellular death may indicate that the protein's mechanisms differ from one form of cancer to another, Ueno said.

PEA-15 is a versatile protein, serving multiple cellular functions, including glucose metabolism and regulating the tumor necrosis factor (TNF) pathway in addition to its role regulating ERK, Ueno said.

"We are committed to further developing PEA-15 and making it a druggable target," Ueno said. The team is developing a non-gene therapy treatment because adenovirally delivered gene therapies such as those used to overexpress PEA-15 in the mouse experiments have had less success in humans.

Funding for this research was provided by a Susan G. Komen Postdoctoral Fellowship to Bartholomeusz and a National Cancer Institute grant to Ueno.

Co-authors with Bartholomeusz and Ueno are Linda Yuan, Fumiyuki Yamasaki, M.D., Ph.D., Anna Kazansky, Dongwei Zhang, M.D., PhD, Francisco Esteva, M.D., Ph.D., and Gabriel Hortobagyi, M.D., all of M. D. Anderson's Breast Cancer Translational Research Laboratory and the Department of Breast Medical Oncology; and Savithri Krishnamurthy, M.D., of M. D. Anderson's Department of Pathology.

About M. D. Anderson

The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For four of the past six years, including 2008, M. D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>